Investigating REC-1245 for advanced or metastatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multi-center, open-label study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of REC-1245, an oral medication administered once daily, in participants with unresectable, locally advanced, or metastatic solid tumors. Approximately 85 individuals will be enrolled, with 55 in Phase 1 and 10-30 in Phase 2, receiving treatment for up to 2 years. The study focuses on those who have experienced disease progression or have been intolerant to standard therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed / refractory lymphoma
* Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.
* Eastern cooperative oncology group (ECOG) performance status ≤1; for adolescent participants, Lansky Performance Status Scale or Karnofsky Performance Status Scale score of ≥70.
* Measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 / Lugano criteria and documented by computed tomography (CT) and / or magnetic resonance imaging (MRI)

Exclusion Criteria:

* Received treatment with another RBM39 degrader
* Clinically significant gastrointestinal (GI) or GI malabsorption

Where it's running

• City of Hope
  Duarte, California, United States Recruiting
• Sarcoma Oncology Research Center
  Santa Monica, California, United States Recruiting
• Cleveland Clinic
  Cleveland, Ohio, United States Recruiting
• START Mountain Region
  West Valley City, Utah, United States Recruiting
• Princess Margaret Cancer Centre
  Toronto, Ontario, Canada Recruiting
• McGill University Health Centre (MUHC) - The Montreal
  Québec, Canada Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• YntraDose™ given before chemotherapy for locally advanced, unresectable pancreatic cancer

  This will test whether a one-time, image-guided injection of YntraDose™ (Y-90 radioactive microspheres) into the pancreatic tumor, combined with standard chemotherapy, is safe and can help control locally advanced unresectable pancreatic cancer.

  Recruiting at 2 sites BetaGlue Therapeutics SpA · Roma and 1 other locations · NCT07155850

• Accelerated immuno chemoradiotherapy for advanced lung cancer

  This study is testing a new fast treatment combining radiation and chemotherapy for people with advanced lung cancer to see if it works better than the usual approach.

  Recruiting at 10 sites Phase 2 TheraOp · Dresden and 10 other locations · NCT06102057

• Dual PD1/CTLA4 immunotherapy with chemotherapy before surgery for locally advanced cervical cancer

  This study tests a combo of a PD1/CTLA4 bispecific antibody with standard chemotherapy to see if it can improve outcomes before surgery in women with locally advanced cervical cancer.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07646301

• e-Motion: Promoting Emotion Regulation for People Living with Chronic Cancer

  This pilot tests two emotion-regulation programs—a guided self-help program and a combined group plus guided self-help program—for people recently diagnosed with metastatic or other chronic cancers.

  Recruiting Université Libre de Bruxelles · Brussels, Anderlecht and 1 other locations · NCT07236021

• AVZO-103 alone and with other treatments for advanced urothelial and other solid tumors

  This trial will test intravenous AVZO-103, alone and combined with other cancer drugs, to see if it is safe and helps adults with locally advanced or metastatic urothelial cancer or other solid tumors.

  Recruiting at 15 sites Phase 1/2 Avenzo Therapeutics, Inc. · San Francisco, California and 14 other locations · NCT07193511

• CUE-101 with pembrolizumab for locally advanced HPV‑16 positive oropharyngeal cancer

  This trial tests whether CUE-101 alone or combined with pembrolizumab before definitive therapy helps people with newly diagnosed, locally advanced HPV‑16 positive oropharyngeal cancer who are HLA‑A*02:01 positive.

  Recruiting Phase 2 Yale University · New Haven, Connecticut · NCT07172256

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.